REPL News and Press, Replimune Group Inc. From 09/19/25

2025-09-19 11:17:20 ET More on Replimune Group Replimune Group: The Prospects For FDA Approval After Rejection Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program Replimune down amid uncertainty over accelerated approval Replimune gains as FDA...

A look at the top 10 most actives in the United States Adaptimmune Therapeutics plc (ADAP) rose 98.0% to $0.16 on volume of 728,354,687 shares Intel Corporation (INTC) rose 22.8% to $30.57 on volume of 520,197,517 shares Datavault AI Inc. (DVLT) rose 21.0% to $0.4147 on volume of 294,006,45...

A look at the top 10 most actives in the United States Datavault AI Inc. (DVLT) rose 31.7% to $0.45145 on volume of 160,605,677 shares Intel Corporation (INTC) rose 24.7% to $31.06 on volume of 160,224,243 shares Aptevo Therapeutics Inc. (APVO) rose 67.7% to $2.365 on volume of 66,397,378 s...

REPL 6-DAY DEADLINE ALERT: Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman PR Newswire REPL Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Sept. 16, 2025 /PRNewswire/ -- A new secur...

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm PR Newswire NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor...

New York, New York--(Newsfile Corp. - September 9, 2025) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Replimune Group, Inc. (NASDAQ: REPL) breached their fiduciary duties to shareholders. According to a federal securities l...

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm PR Newswire NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global inv...

The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by th...

Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman PR Newswire SAN FRANCISCO , Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its ...

Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman PR Newswire SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback th...